en
svPress releases
Regulatory press release 2025-08-12
Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds
Regulatory press release 2025-07-11
XSpray Pharma achieves significant milestone – demonstrating bioequivalence with absorption advantages compared to Tasigna
Regulatory press release 2025-06-27
Xspray Pharma Passes FDA Pre-Approval Inspection – Key Regulatory Milestone Achieved for Dasynoc
Regulatory press release 2025-05-14
FDA sets PDUFA-date for Xspray Pharma’s re-submitted application for Dasynoc®
Regulatory press release 2025-05-13
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2025-05-07
Interim Report First Quarter 2025
Regulatory press release 2025-04-10
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2025-03-27
Xspray Pharma AB publishes its Annual Report for 2024
Regulatory press release 2025-02-12
Interim Report Fourth Quarter 2024
Regulatory press release 2024-12-30